Bullish Ryman Healthcare Insiders Loaded Up On NZ$2.68m Of Stock

Over the last year, a good number of insiders have significantly increased their holdings in Ryman Healthcare Limited (NZSE:RYM). This is encouraging because it indicates that insiders are more optimistic about the company's prospects.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

See our latest analysis for Ryman Healthcare

The Last 12 Months Of Insider Transactions At Ryman Healthcare

In the last twelve months, the biggest single purchase by an insider was when insider Kevin Hickman bought NZ$2.0m worth of shares at a price of NZ$5.00 per share. We do like to see buying, but this purchase was made at well below the current price of NZ$5.73. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Over the last year, we can see that insiders have bought 523.39k shares worth NZ$2.7m. On the other hand they divested 20.27k shares, for NZ$135k. In the last twelve months there was more buying than selling by Ryman Healthcare insiders. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Ryman Healthcare is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insiders At Ryman Healthcare Have Sold Stock Recently

Over the last three months, we've seen significant insider selling at Ryman Healthcare. In total, insiders sold NZ$135k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.

Insider Ownership Of Ryman Healthcare

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Ryman Healthcare insiders own 4.9% of the company, currently worth about NZ$193m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Ryman Healthcare Insider Transactions Indicate?

Insiders sold Ryman Healthcare shares recently, but they didn't buy any. On the other hand, the insider transactions over the last year are encouraging. And insider ownership remains quite considerable. So we're not too bothered by recent selling. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To assist with this, we've discovered 4 warning signs that you should run your eye over to get a better picture of Ryman Healthcare.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.